Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score
Study Type: Treatment
Phase: III
NCTID: NCT05879926
Principal Investigator:
Lauren Nye
Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer
Study Type: Treatment
Phase: III
NCTID: NCT03488693
Principal Investigator:
Julia White
EXActDNA-003: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease NSABP B-64
Study Type: Other
Phase: N/A
NCTID: NCT06401421
Principal Investigator:
Julia White
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring STMDDM versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
Study Type: Health Services
Phase: N/A
NCTID: NCT03723928
Principal Investigator:
Gary Doolittle
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer SCARLET, A Randomized Phase III Study
Study Type: Treatment
Phase: III
NCTID: NCT05929768
Principal Investigator:
Priyanka Sharma
Breast Tissue Biomarkers Predicting Short Term Risk of Breast Cancer
Study Type: Screening
Phase: N/A
NCTID: NCT00291096
Principal Investigator:
Carol Fabian
Evaluation of the FLIR One Dynamic Thermal Imaging System in Autologous Breast Reconstruction
Study Type: Health Services
Phase: N/A
NCTID: NCT00000000
Principal Investigator:
Eric Lai
Prospective evaluation of GErmline mutations, Cancer outcome and Tissue biomarkers P.R.O.G.E.C.T.: A registry for patients with triple negative breast cancer and germline mutations
Study Type: Other
Phase: N/A
NCTID: NCT02302742
Principal Investigator:
Priyanka Sharma
A Phase III Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative HR+/HER2- Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor
Study Type: Treatment
Phase: III
NCTID: NCT06982521
Principal Investigator:
Yiduo Hu
A Phase I, First-in-Human Study of MEN2312, a KAT6 inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer
Study Type: Treatment
Phase: I
NCTID: NCT06638307
Principal Investigator:
Priyanka Sharma